Story
NHTSA Orders Tesla to Detail Cybercab Safety Certification by Sept. 30

Summary
The National Highway Traffic Safety Administration has formally ordered Tesla to answer questions about its self-certification process for the autonomous Cybercab, focusing on the use of temporary human controls.
The U.S. National Highway Traffic Safety Administration (NHTSA) has ordered Tesla to provide detailed answers regarding the safety self-certification of its autonomous Cybercab robotaxi. According to a Reuters report on Tuesday, the automaker must respond to the agency's questions by September 30 as part of an ongoing government investigation.
Scrutiny Over Certification Basis
The federal auto safety regulator is specifically probing the basis for Tesla's declaration that the vehicle complies with U.S. safety standards. A key point of the inquiry is whether the company used temporarily installed human driver controls or other non-standard equipment to certify the vehicle's safety.
NHTSA's order requires Tesla to clarify if such temporary equipment formed the basis for its compliance certification. The investigation raises questions about whether the version of the Cybercab that was certified is materially different from the fully autonomous version intended for public use, which would lack traditional driver controls.
AdContext and Implications
In the United States, automakers self-certify that their vehicles meet Federal Motor Vehicle Safety Standards, with NHTSA holding the authority to investigate and enforce compliance. This inquiry places a spotlight on the established regulatory process as it applies to novel vehicle designs like autonomous robotaxis that lack conventional features like steering wheels or pedals.
The Cybercab is a significant future product for Tesla, central to its plans for a fully autonomous ride-hailing network. Regulatory hurdles and investigations into the safety and certification of its autonomous technology are closely watched by investors. On Tuesday, shares of Tesla (TSLA) were trading down approximately 0.55%.
Read next
More on Stocks
Novo Nordisk, Orbis Medicines Ink $1.4 Billion Deal for Oral Cardiometabolic Drugs
Orbis Medicines and Novo Nordisk have entered a licensing collaboration potentially worth up to $1.4 billion to develop oral versions of injectable drugs for cardiometabolic diseases, leveraging Orbis's AI-driven discovery platform.

Robinhood Shares Rise After SEC Issues Guidance on Tokenized Securities
Shares of Robinhood Markets (HOOD) climbed after the U.S. Securities and Exchange Commission introduced a five-year plan allowing for the trading of tokenized stocks on designated venues.

Gold Prices Face Near-Term Pressure From Strong US Data, Higher Yields
Gold is trading in a narrow range as robust economic indicators bolster Treasury yields, creating headwinds for the non-yielding asset. The medium-term outlook remains constructive, contingent on a potential shift in monetary policy and persistent structural demand.

UBS Upgrades Industrial Metals to Overweight, Citing Long-Term Structural Tailwinds
UBS has raised its outlook on industrial metals to Overweight, arguing that structural forces like the energy transition and chronic underinvestment will support prices in the coming years.